×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LCTX – lineage cell therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LCTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/10
04:34 pm
lctx
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/10
04:05 pm
lctx
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/5
08:18 am
lctx
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 [Yahoo! Finance]
Medium
Report
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 [Yahoo! Finance]
3/5
08:00 am
lctx
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
Medium
Report
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
2/11
08:33 am
lctx
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury [Yahoo! Finance]
Medium
Report
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury [Yahoo! Finance]
2/11
08:00 am
lctx
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Low
Report
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
2/4
08:37 am
lctx
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference [Yahoo! Finance]
Medium
Report
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference [Yahoo! Finance]
2/4
08:00 am
lctx
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Medium
Report
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Date
Time
Symbol
Company Name
Action
%Chg
3/10/2025
04:05 pm
LCTX
lineage cell therapeutics, inc.
BEAT
Report
-2.2%
lineage cell therapeutics, inc.
3/10/2025
04:05 pm
LCTX
lineage cell therapeutics, inc.
BEAT
Report
-2.2%
lineage cell therapeutics, inc.
3/10/2025
04:05 pm
LCTX
lineage cell therapeutics, inc.
BEAT
Report
-2.2%
lineage cell therapeutics, inc.
3/10/2025
04:05 pm
LCTX
lineage cell therapeutics, inc.
BEAT
Report
-2.2%
lineage cell therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/24
Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets
25.2%
2/10 Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference 18.5%
12/30 Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration 14.3%
2/6 Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration 13.9%
4/29 Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020 12.7%
3/17 Lineage Cell Therapeutics, Inc. (NASDAQ: LCTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. 9.8%
11/15 Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program 9.4%
8/13 Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program 7.4%
3/12 Q4/2019 12/31/2019 EPS -0.030 ZacksConsensus -0.070 ActVsEst 0.040 - Beat 7.2%
11/5 Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 4.9%
2/10 Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference 18.5%
12/30 Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration 14.3%
2/6 Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration 13.9%
4/29 Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020 12.7%
3/17 Lineage Cell Therapeutics, Inc. (NASDAQ: LCTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. 9.8%
11/15 Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program 9.4%
8/13 Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program 7.4%
3/12 Q4/2019 12/31/2019 EPS -0.030 ZacksConsensus -0.070 ActVsEst 0.040 - Beat 7.2%
11/5 Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 4.9%
TOP News Decliners
8/26
Lineage Cell Therapeutics Announces Issuance of U.S. Patent for System for Generating Immunogenic Dendritic Cells
-11.0%
8/12 Lineage Cell Therapeutics Launches New Corporate Brand -9.2%
9/26 Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019 -9.1%
12/10 Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells -6.7%
12/19 Lineage Cell Therapeutics Provides Shareholder Update -4.8%
3/5 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020 -4.1%
9/23 Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019 -3.7%
10/14 Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting -3.0%
9/4 Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells -2.2%
9/10 Lineage Cell Therapeutics (LCTX ) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow [Seeking Alpha] -1.9%
8/12 Lineage Cell Therapeutics Launches New Corporate Brand -9.2%
9/26 Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019 -9.1%
12/10 Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells -6.7%
12/19 Lineage Cell Therapeutics Provides Shareholder Update -4.8%
3/5 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020 -4.1%
9/23 Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019 -3.7%
10/14 Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting -3.0%
9/4 Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells -2.2%
9/10 Lineage Cell Therapeutics (LCTX ) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow [Seeking Alpha] -1.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: